DexCom, Inc. (NASDAQ:DXCM – Get Rating) CEO Kevin R. Sayer sold 45,607 shares of the company’s stock in a transaction on Friday, January 20th. The shares were sold at an average price of $105.75, for a total transaction of $4,822,940.25. Following the sale, the chief executive officer now directly owns 426,645 shares in the company, valued at approximately $45,117,708.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
DexCom Trading Down 0.3 %
Shares of NASDAQ DXCM traded down $0.37 during mid-day trading on Tuesday, reaching $106.03. The company had a trading volume of 1,685,571 shares, compared to its average volume of 2,616,071. The company has a current ratio of 3.77, a quick ratio of 3.43 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 52 week low of $66.89 and a 52 week high of $134.76. The business’s 50-day moving average is $113.06 and its 200-day moving average is $99.19. The stock has a market cap of $40.95 billion, a price-to-earnings ratio of 196.13, a price-to-earnings-growth ratio of 2.95 and a beta of 1.14.
DexCom (NASDAQ:DXCM – Get Rating) last issued its earnings results on Thursday, October 27th. The medical device company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.04. DexCom had a net margin of 8.24% and a return on equity of 13.27%. The company had revenue of $769.60 million for the quarter, compared to analysts’ expectations of $752.67 million. Equities analysts expect that DexCom, Inc. will post 0.79 earnings per share for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the stock. Cowen increased their target price on shares of DexCom from $85.00 to $114.00 in a research note on Friday, October 28th. Piper Sandler increased their target price on shares of DexCom to $130.00 in a research note on Tuesday, November 1st. Wells Fargo & Company increased their target price on shares of DexCom from $102.00 to $128.00 and gave the company an “overweight” rating in a research note on Friday, October 28th. Morgan Stanley increased their target price on shares of DexCom from $117.00 to $131.00 and gave the company an “equal weight” rating in a research note on Friday, January 6th. Finally, Stifel Nicolaus increased their target price on shares of DexCom from $120.00 to $130.00 in a research note on Tuesday, December 20th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $122.00.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.
- Get a free copy of the StockNews.com research report on DexCom (DXCM)
- Insiders Buy Archer Aviation, Is This Stock About To Take Off?
- Intuit Is About To Make a Move, But Which Way?
- 3 Late January Earnings Plays With Pop Potential
- Low-Priced Stocks Still Paying Dividends
- Why is the Chipotle Stock Price Surging This Week?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.